Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

ALVOVery BearishCorporate Developmentsnews

High materiality9/10

Alvotech Shares Plunge 33% After FDA Flags Issues

Nov 3, 2025, 1:41 PM EST1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The CRL indicates significant regulatory setbacks. Historical precedent shows similar stock declines for biotech firms post-CRL.

AI summary

What happened, with direct paths to the underlying reporting

ALVO received a complete response letter (CRL) from the FDA. Deficiencies noted in the BLA for AVT05 biosimilar to Simponi. Total revenue outlook for 2025 revised to $570-$600 million. ALVO stock dropped 33.99% to $5.05 following the news. Current FDA approvals for a Simponi biosimilar remain unachieved.

ALVO received a complete response letter (CRL) from the FDA.
Deficiencies noted in the BLA for AVT05 biosimilar to Simponi.
Total revenue outlook for 2025 revised to $570-$600 million.
ALVO stock dropped 33.99% to $5.05 following the news.
Current FDA approvals for a Simponi biosimilar remain unachieved.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Alvotech Shares Plunge 33% After FDA Flags Issues

Dr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer Drug